IL160272A0 - Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist - Google Patents

Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist

Info

Publication number
IL160272A0
IL160272A0 IL16027202A IL16027202A IL160272A0 IL 160272 A0 IL160272 A0 IL 160272A0 IL 16027202 A IL16027202 A IL 16027202A IL 16027202 A IL16027202 A IL 16027202A IL 160272 A0 IL160272 A0 IL 160272A0
Authority
IL
Israel
Prior art keywords
pde3
pde4
inhibitor
pharmaceutical compositions
leukotriene receptor
Prior art date
Application number
IL16027202A
Other languages
English (en)
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of IL160272A0 publication Critical patent/IL160272A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16027202A 2001-09-19 2002-09-17 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist IL160272A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000474 2001-09-19
PCT/EP2002/010423 WO2003024488A2 (fr) 2001-09-19 2002-09-17 Nouvelle combinaison

Publications (1)

Publication Number Publication Date
IL160272A0 true IL160272A0 (en) 2004-07-25

Family

ID=8176066

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16027202A IL160272A0 (en) 2001-09-19 2002-09-17 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist
IL160272A IL160272A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160272A IL160272A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist

Country Status (26)

Country Link
US (1) US20050014762A1 (fr)
EP (1) EP1429843B1 (fr)
JP (1) JP2005505570A (fr)
KR (1) KR20040044946A (fr)
CN (1) CN100346831C (fr)
AT (1) ATE349243T1 (fr)
BR (1) BR0212582A (fr)
CA (1) CA2460442A1 (fr)
CO (1) CO5560584A2 (fr)
CY (1) CY1106365T1 (fr)
DE (1) DE60217139T2 (fr)
DK (1) DK1429843T3 (fr)
EA (1) EA007736B1 (fr)
ES (1) ES2279004T3 (fr)
HK (1) HK1066752A1 (fr)
HU (1) HUP0500078A3 (fr)
IL (2) IL160272A0 (fr)
MA (1) MA27136A1 (fr)
MX (1) MXPA04002560A (fr)
NO (1) NO331885B1 (fr)
NZ (1) NZ532279A (fr)
PL (1) PL205927B1 (fr)
PT (1) PT1429843E (fr)
SI (1) SI1429843T1 (fr)
WO (1) WO2003024488A2 (fr)
ZA (1) ZA200402653B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
AU2008316283A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd Inhalation compositions comprising montelukast acid and a PDE-4 inhibitor or an inhaled corticosteroid
WO2012168907A1 (fr) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant du révamilast et du montélukast ou du zafirlukast
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
WO2015063669A1 (fr) 2013-10-30 2015-05-07 Wockhardt Limited Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables
WO2015110394A1 (fr) 2014-01-22 2015-07-30 Takeda Gmbh Traitement de l'asthme grave partiellement contrôlé ou non contrôlé avec un inhibiteur de pde4 (et en combinaison avec un modificateur des leucotriènes)
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
BR112017001334A2 (pt) 2014-08-06 2017-11-14 Pfizer compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
PT1212089E (pt) * 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
AU2700201A (en) * 2000-01-31 2001-08-14 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU2001261962B2 (en) * 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor

Also Published As

Publication number Publication date
CN1655846A (zh) 2005-08-17
HUP0500078A2 (hu) 2005-04-28
PT1429843E (pt) 2007-03-30
JP2005505570A (ja) 2005-02-24
HK1066752A1 (en) 2005-04-01
ZA200402653B (en) 2005-02-14
KR20040044946A (ko) 2004-05-31
HUP0500078A3 (en) 2010-07-28
NZ532279A (en) 2006-02-24
PL367414A1 (en) 2005-02-21
EP1429843A2 (fr) 2004-06-23
MA27136A1 (fr) 2005-01-03
CA2460442A1 (fr) 2003-03-27
NO20041595L (no) 2004-06-16
IL160272A (en) 2008-03-20
EA200400416A1 (ru) 2004-12-30
DE60217139T2 (de) 2007-10-04
WO2003024488A3 (fr) 2003-09-04
EP1429843B1 (fr) 2006-12-27
DK1429843T3 (da) 2007-04-30
NO331885B1 (no) 2012-04-30
CN100346831C (zh) 2007-11-07
BR0212582A (pt) 2004-10-13
DE60217139D1 (de) 2007-02-08
CO5560584A2 (es) 2005-09-30
ATE349243T1 (de) 2007-01-15
CY1106365T1 (el) 2011-10-12
EA007736B1 (ru) 2006-12-29
US20050014762A1 (en) 2005-01-20
SI1429843T1 (sl) 2007-06-30
WO2003024488A2 (fr) 2003-03-27
PL205927B1 (pl) 2010-06-30
MXPA04002560A (es) 2004-05-31
ES2279004T3 (es) 2007-08-16

Similar Documents

Publication Publication Date Title
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
GEP20084571B (en) Triazole derivatives as vasopressin antagonists
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
HK1065540A1 (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
HUP0401656A3 (en) Mch antagonists for the treatment of obesity and pharmaceutical compositions containing them
HUP0105488A3 (en) Monoamine reuptake inhibitors for treatment of cns disorders and pharmaceutical compositions containing the compounds
HUP0304058A2 (hu) Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0400349A3 (en) Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
HUP0202862A2 (hu) A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény
HUP0204458A3 (en) Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them
HUP0104085A3 (en) Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension
HUP0302068A3 (en) Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
WO2002081728A3 (fr) Inhibiteurs quinoline des kinases hyak1 et hyak3
ID29818A (id) Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial
BR0000486A (pt) Antagonistas do neuropeptìdeo y
HUP0401858A3 (en) Gal3 receptor antagonist pyrimidine and indolone-derivatives and their use for preparation of pharmaceutical compositions suitable for the treatment of depression and/or anxiety
HUP0302820A3 (en) Indole derivatives useful for the treatment of cns disorders and pharmaceutical compositions containing them
NO20033634L (no) GLyT-1-inhibitorer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed